Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus. (PEDF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01809093|
Recruitment Status : Completed
First Posted : March 12, 2013
Last Update Posted : February 23, 2017
|Condition or disease||Intervention/treatment|
|Diabetes Diabetes Mellitus||Biological: Blood draw|
|Study Type :||Observational|
|Actual Enrollment :||90 participants|
|Official Title:||Modulation of Thrombospondin-1 and Pigment Epithelium Derived Factor Levels in Vitreous Fluid and Plasma of Patients With Diabetes|
|Study Start Date :||March 2010|
|Actual Primary Completion Date :||March 2014|
|Actual Study Completion Date :||March 2014|
Blood (approximately equal to 3 to 4 tablespoons) will be drawn at the Wills Eye Institute, 1 time.
Biological: Blood draw
3-4 tablespoons of blood will be drawn, one time.
- Level of thrombospondin (TSP1) and pigment epithelium derived factor (PEDF) in the vitreous and plasma [ Time Frame: up to 6 months ]Your voluntary participation in this study may help determine how different TSP1 and PEDF levels correlate with diabetic eye disease.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01809093
|United States, Pennsylvania|
|Mid Atlantic Retina- Wills Eye Institute|
|Philadelphia, Pennsylvania, United States, 19107|
|Principal Investigator:||Marc Spirn, M.D.|